1. Pink Sheet
  2. >>Legislation

AHIP, PhRMA Try to Control Narrative as Heat on PBMs Intensifies

 
• By Leslie Small

As health insurance lobby launches advertising campaign to defend ‘evidence-based, market-driven tools,’ drug firms point out the connection between insurers and pharmacy benefit managers.

Pills in dollars
With the spotlight on PBMs, AHIP appears to be trying to prevent spillover. • Source: Shutterstock

The health insurer trade group AHIP recently unveiled a new advertising campaign that accuses the pharmaceutical industry of deflecting blame for its “price-gouging” practices and undermining the “evidence-based, market-driven tools” that health insurers use to keep drug costs in check. But the campaign doesn’t appear to mention PBMs, even though they’re the ones conducting drug-price negotiations with manufacturers on behalf of health plans and employers.

Health care industry observers say that omission is unsurprising since PBMs are currently facing a growing wave of scrutiny —...

More from Legislation

More from Pink Sheet

Project Orbis: 2025 Shaping Up To Be A Strong Year For Canadian Approvals

 
• By Eliza Slawther

Health Canada has approved four new drugs and 12 label variations so far this year via Project Orbis, a combined figure that already exceeds the annual approval figures for the two previous years. The agency explains the factors that impact annual approvals and highlights the pathway’s benefits.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include three new products, one of which is Rezdiffra, Madrigal Pharmaceuticals’s treatment for metabolic dysfunction-associated steatohepatitis.

MHRA Backs Global AI Framework For Pharmacovigilance Over UK-Specific Guidance

 
• By Vibha Sharma

The UK’s medicines regulator wants to ensure that guidance on the use of artificial intelligence in pharmacovigilance processes remains fit for the future.